文献速递淋巴瘤

当代一线治疗后复发难治性霍奇金淋巴瘤的临床结局:德国霍奇金研究组分析

Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis.
PubMed 文献 · Leukemia · 2021-10-09

该研究基于德国霍奇金研究组数据库,纳入409例首次复发难治性霍奇金淋巴瘤患者,评估当代一线治疗后的复发模式与生存结局。中位年龄37.4岁,49%患者首次复发时间≤12个月,52%为III/IV期。首次复发后10年无进展生存率和总生存率分别为48.2%和59.4%,亚组间差异显著。

要点

  • 首次复发后10年PFS为48.2%,OS为59.4%,亚组间差异显著。
  • 因高龄/合并症未行ASCT或挽救治疗失败者5年PFS约36%。
  • 低危患者即使未行ASCT,10年PFS仍可达72.6%。

核心结论

  • 研究证实当前复发难治性霍奇金淋巴瘤治疗具有治愈潜力,为评估新策略提供基准。
  • 约50%的复发难治性霍奇金淋巴瘤患者经历连续复发。

研究设计与样本

  • 基于德国霍奇金研究组数据库的回顾性分析,纳入409例首次复发难治性霍奇金淋巴瘤患者。
  • 患者来自HD13(n=87)、HD14(n=118)、HD15(n=188)和HDR3i(n=51)研究,中位年龄37.4岁(范围18.4-76.8)。

主要发现

  • 首次复发时间≤12个月者占49%,III/IV期复发难治性霍奇金淋巴瘤占52%。
  • 291例接受大剂量化疗联合自体干细胞移植(ASCT),38例拟行ASCT但失败,80例主要因低危疾病或年龄/合并症未计划ASCT。
  • 首次复发后10年无进展生存率为48.2%(95% CI 41.9-54.2%),总生存率为59.4%(95% CI 53.0-65.2%)。
  • 因高龄/合并症未行ASCT者5年PFS为36.2%(95% CI 17.7-55.0%),挽救治疗失败者5年PFS为36.3%(95% CI 19.7-53.2%)。
  • 低危患者即使未行ASCT,10年PFS为72.6%(95% CI 53.7-84.8%)。

关键数值与推荐

  • 原发性难治性疾病或复发难治性霍奇金淋巴瘤时IV期提示生存较差。
  • 低危疾病患者即使未行ASCT,10年PFS达72.6%(95% CI 53.7-84.8%)。

临床怎么用

  • 对复发难治性霍奇金淋巴瘤患者,应根据风险分层(如复发时间、分期、原发难治)和年龄/合并症决定是否行ASCT。
  • 低危患者可能在不进行ASCT的情况下获得较好生存,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To evaluate patterns of rrHL after contemporary first-line treatment we studied 409 patients with first rrHL (HD13: n = 87, HD14: n = 118, HD15: n = 188, HDR3i: n = 51) at a median age of 37.4 years (18.4-76.8) from the GHSG database. Time to first relapse was ≤12 months in 49% and stage III/IV rrHL present in 52% of patients. In total, 291 patients received high-dose chemotherapy and autologous stem-cell transplantation (ASCT) and intended ASCT failed in 38 patients. ASCT was primarily not intended in 80 patients largely due to low risk disease or age/comorbidities. Overall, 10-year progression-free (PFS) and overall survival (OS) rates after first relapse were 48.2% (95% CI 41.9-54.2%) and 59.4% (95% CI 53.0-65.2%), respectively, with significant differences between subgroups. Inferior survival was observed with no ASCT due to advanced age/comorbidities (five-year PFS 36.2%, 95% CI 17.7-55.0%) or failure of salvage therapy (five-year PFS 36.3%, 95% CI 19.7-53.2%). Similarly, presence of primary refractory disease or stage IV at rrHL conferred inferior survival. In patients with low-risk disease, however, survival appeared favorable even without ASCT (10 y PFS 72.6%, 95% CI 53.7-84.8%). We herein confirm the curative potential of current rrHL treatments providing a robust benchmark to evaluate novel therapeutic strategies in rrHL. Approximately 50% of rrHL patients experienced a consecutive relapse.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Bröckelmann PJ, Müller H, Gillessen S, et al. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. Leukemia. 2021. PMID: 34628472. doi:10.1038/s41375-021-01442-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。